$MEDP

McCarthy Cornelius P. III sold $690K of MEDP

McCarthy Cornelius P. III sold 1,140 shares of Medpace Holdings, Inc. (MEDP) at $605.37 ($0.69M total) on 2026-08-11.

Original reporting
SEC EDGAR · McCarthy Cornelius P. III
Published Aug 13, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MEDP
Neutral
medium confidence
Mentioned
$MEDP
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale details (shares, price, total value, and post-transaction holdings). There is no new operational, financial, or regulatory information about Medpace.

02

Market read

Traders may briefly monitor insider activity, but this specific disclosure does not change Medpace’s fundamentals based on the provided text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, the signal-to-noise is low.

Relevance 5/10Novelty 3/10Timing: Form 4 filed 2026-08-13 for a sale dated 2026-08-11.

Background

The article is an SEC Form 4 insider transaction disclosure for Medpace Holdings, Inc. (MEDP).

Company-level read

Ticker impact

$MEDPNeutralMedium confidence
Context

Medpace director McCarthy sold 1,140 shares in an open-market transaction at $605.37 on 2026-08-11, per Form 4 filed 2026-08-13.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction. The article provides transaction size, price, and post-sale holdings, but no accompanying company news, earnings, or operational update.

Market effects

Minimal. Insider sales typically do not reset sector expectations without accompanying company-specific news.

None indicated.

None indicated.

Counterpoint

Because the filing states no pre-arranged 10b5-1 plan, some traders may interpret the sale as a stronger signal than a typical planned transaction, even though the article lacks context.

Key entities

  • Medpace Holdings, Inc.

    Subject of the Form 4 insider sale disclosure.

  • McCarthy Cornelius P. III

    Director who sold 1,140 shares at $605.37 per share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.